… that key mutations in the N-terminal domain can reduce the neutralizing capacity of … a
combination of two neutralizing antibodies targeting the receptor-binding and N-terminal domains …

… neutralizing antibodies using the virus receptor-binding … (SP); N-terminal domain (NTD);
receptor-binding domain (RBD), … To overcome the limitations of monovalent sdAbs, 30 sdAbs …

… IgG Fc-domain to overcome the limitations of the monovalent … In conclusion, the discovered
neutralizing antibodies in this … with N-terminal interleukin-2 signal peptide and C-terminal Fc …

… Authorizations to two combination products, bamlanivimab … (aa 17–740) with an N-terminal
CD33 signal peptide and a dual C-… neutralization potency of mouse sera reached a maximum …

… to the receptor binding domain (RBD), S1 has an N-terminal … SARS-CoV-2–neutralizing
antibodies that target the RBD and … Combination of 4A8 with RBD-targeting antibodies may avoid …

… The S1 domain contains an N-terminal domain (NTD) and the RBD that connects to two
subdomains (SD1, SD2) at the C-terminus. The RBD transiently switches between an up state …

… Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain
or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies …

… CP samples spanning the minimum to maximum range. … One set was produced with N-terminal
biotin, and these peptides were used with streptavidin coated ELISA plates. Another set …

… antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike (S) protein receptor-binding
domain and block … that the RBD region is a key target for potently neutralizing antibodies ( …

… contains an immunodominant receptor-binding domain (RBD) targeted by most neutralizing
antibodies (Abs) in COVID-19 patient plasma. Little is known about neutralizing Abs binding …